AOD-9604

Research

AOD-9604 (HGH Fragment 176-191)

Aliases
HGH Fragment 176-191, Anti-Obesity Drug 9604
Administration
Subcutaneous injection

Timing

A general projection of what people report noticing over time, based on the known mechanism and reported use patterns. It is not a guarantee and individual experience varies considerably.

  1. 1

    1–2 Weeks

    Most users do not report a distinct early sensation, consistent with trial results showing limited effect versus placebo.

  2. 2

    3–4 Weeks

    Any fat-loss-related sensation tends to be subtle, if present at all.

  3. 3

    5–7 Weeks

    Continued use has not been shown to produce a clearly felt difference in available research.

  4. 4

    8–10 Weeks

    Users generally do not report a strong distinguishing sensation at this stage.

  5. 5

    11–15 Weeks

    Available evidence does not support expecting a pronounced felt effect through this window.

  6. 6

    16–20 Weeks

    Any changes reported by users during this period are difficult to distinguish from diet and exercise alone.

  7. 7

    21–24 Weeks

    By this stage, most users evaluating this compound rely on measured outcomes rather than felt sensation, given the mixed clinical evidence.

⚠️ Research context only. This is not medical advice and results are not guaranteed.